QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

ROIV

QT53Roivant Sciences Ltd.
NASDAQ·Healthcare·Biotechnology·UK
Latest market price
31.43
+0.23+0.74%
OverviewShort InterestFilings
ROIVQT53Roivant Sciences Ltd.·NASDAQ
OverviewShort InterestFilings
31.43+0.74%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-0.51
Insider Own25.16%
Shs Outstand719.27M
Perf Week5.72%
Market Cap22.44BForward P/E-EPS next Y-0.98Insider Trans1.45%Shs Float-Perf Month11.41%
Enterprise Value21.13BPEG0.87EPS next Q-0.33Inst Own-Short Float-Perf Quarter13.06%
Income-307444769.00P/S2716.86EPS this Y-145.83%Inst Trans-Short Ratio-Perf Half Y37.01%
Sales8.26MP/B4.84EPS next Y21.77%ROA-5.23%Short Interest-Perf YTD44.84%
Book/sh7.36P/C-EPS next 5Y-ROE-6.85%52W High32.79 -4.15%Perf Year182.90%
Cash/sh5.97P/FCF-EPS past 3/5Y-ROIC-23.55%52W Low10.71 193.46%Perf 3Y-
Dividend Est.-EV/EBITDA-80.87Sales past 3/5Y-37.00% -19.73%Gross Margin84.44%Volatility2.32% 2.77%Perf 5Y-
Dividend TTM-EV/Sales2557.58EPS Y/Y TTM-275.47%Oper. Margin-15560.57%ATR (14)1.06Perf 10Y-
Dividend Ex-Date-Quick Ratio18.37Sales Y/Y TTM-68.97%Profit Margin-3629.19%RSI (14)62.42Recom2.00
Dividend Gr. 3/5Y-Current Ratio18.37EPS Q/Q-26.91%SMA206.02%Beta1.08Target Price37.17
Payout0.00%Debt/Eq0.02Sales Q/Q-62.50%SMA507.89%Rel Volume1.46Prev Close31.20
Employees908LT Debt/Eq0.02EarningsAug 10SMA20033.43%Avg Volume5.67MPrice31.43
IPO DateDec 08, 2020Option/ShortYes / YesEPS/Sales Surpr.3.49% 0.00%Net Debt/EBITDA5.04Volume8,262,871Change0.74%
Analyst Ratings
DateActionAnalystRatingTarget
May-26-26ReiteratedGuggenheimBuy$30 → $36
May-21-26ReiteratedCowen & Co.Outperform$38 → $41
May-21-26ReiteratedLeerink PartnersOutperform$32 → $42
Apr-16-26ReiteratedPiper SandlerOverweight$20 → $40
Mar-04-26ReiteratedH.C. Wainwright$33 → $34
Feb-10-26ReiteratedH.C. Wainwright$26 → $33
Feb-09-26ReiteratedJefferiesBuy$24 → $30
Feb-09-26ReiteratedGuggenheimBuy$28 → $30
Dec-18-25ReiteratedGuggenheimBuy$25 → $28
Dec-15-25ReiteratedLeerink PartnersOutperform$29 → $32
Latest News
Jun-17-26
Jun-17-2601:46PM
Here is Why Roivant (ROIV) is One of the Best Growth Stocks Trading in Oversold TerritoryYahoo
Jun-11-26
Jun-11-2601:00AM
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline DevelopmentYahoo
01:00AM
Gilead Sciences, Inc. (GILD): a Top Deep Value Stock Making Progress on Pipeline DevelopmentYahoo
Jun-09-26
Jun-09-2608:22PM
Roivant Sciences Ltd. (ROIV) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptSeekingAlpha
05:41PM
Guggenheim Remains Bullish on Roivant Sciences Ltd. (ROIV)Yahoo
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
3/31/2026
FY 2024
3/31/2025
FY 2023
3/31/2024
FY 2022
3/31/2023
FY 2021
3/31/2022
FY 2020
3/31/2021
FY 2019
3/31/2020
Total Revenue9829
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A111
Gross Profit6728
Selling, General and Administrative Excl. Other610610591
Research and Development682682550
Other Operating Expense001
Operating Income-1,285-1,285-1,114
Interest Expense000
Unusual Expense
———
Non-Operating Income (Expense)-1,021-1,021-432
Net Income Before Taxes-264-265-682
Income Taxes13313348
Consolidated Net Income-300-300-172
Net Income From Continuing Operations-398-398-730
Net Income-300-300-172
EPS (Recurring)-0.45-0.43-0.24
EPS (Basic, Before Extraordinaries)-0.45-0.43-0.24
EPS (Diluted)-0.51-0.43-0.24
EBITDA-261-261-668
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio2,451.542,402.98—
Gross Margin66.6787.5096.55
Operating Margin-14,277.78-16,062.50-3,841.38
Net Margin-3,333.33-3,750.00-593.10
Shares Outstanding702694725
Market Capitalization22,06419,224—
Operating Lease Expense
———
Insider Trading Volume
$33.14$29.46$25.77$22.08$18.40● Close Price0.00M67.96M135.93M203.89M271.86MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Venker EricPresident & Immunovant CEOMay 22 '26Option Exercise3.85400,0001,540,0004,444,834May 22 12:00 AM
Venker EricPresident & Immunovant CEOMay 22 '26Sale30.27200,0006,054,0001,613,063May 22 12:00 AM
Venker EricPresident & Immunovant CEOApr 20 '26Option Exercise3.85400,0001,540,0004,644,834Apr 22 12:00 AM
Venker EricPresident & Immunovant CEOApr 20 '26Sale29.59200,0005,918,0001,647,546Apr 22 12:00 AM
Gline MatthewCEOApr 16 '26Sale29.16289,7748,449,81016,736,116Apr 20 12:00 AM
Humes JenniferChief Accounting OfficerApr 08 '26Sale28.3713,538384,07384,191Apr 10 12:00 AM
Gline MatthewCEOMar 30 '26Option Exercise0.542,275,4691,234,00517,384,400Apr 01 12:00 AM
Sukhatme MayukhPresident & CIOMar 30 '26Option Exercise0.541,365,280740,39818,894,938Apr 01 12:00 AM
Fitzgerald MeghanDirectorMar 26 '26Sale27.4570,0001,921,50042,963Mar 30 12:00 AM
Fitzgerald MeghanDirectorMar 26 '26Option Exercise8.80140,0001,232,000112,963Mar 30 12:00 AM
Venker EricPresident & Immunovant CEOMar 17 '26Option Exercise3.85400,0001,540,0004,844,834Mar 19 12:00 AM
Venker EricPresident & Immunovant CEOMar 17 '26Sale28.24200,0005,648,0001,647,546Mar 19 12:00 AM
Epperly Melissa B,DirectorMar 16 '26Sale28.6841,8611,200,57315,804Mar 18 12:00 AM
Torti FrankPresident and Vant ChairFeb 23 '26Sale27.51587,39016,159,09913,736,547Feb 23 12:00 AM
Torti FrankPresident and Vant ChairFeb 23 '26Option Exercise3.851,174,7804,522,90414,323,937Feb 23 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR